The following is a description of a study from one of the many researchers that our organization has funded.

A New Model for Treating Scleroderma

Edwin Chan, M.D.
New York University School of Medicine
New York, New York
Purinergic Signaling in Dermal Fibrosis

Scleroderma is a devastating rheumatic disease affecting many different organs in the body. Unfortunately, there is no effective treatment known at this time. One of the most significant manifestations of scleroderma is thickening of the skin, or dermal fibrosis. This widespread, uncontrolled production of scar tissue not only results in cosmetic disfigurement, but may severely limit daily activity.

Dr. Chan has identified a molecule, adenosine, which plays an important role in dermal fibrosis. Adenosine binds to a specific receptor on the surface of the cell to produce the scarring effect. By blocking these cell surface receptors, Dr. Chan has substantially reduced fibrosis in animal models, providing a new model for treatment. His ANRF-funded study will explore the way adenosine alters fibrosis in the skin. He hopes that the results from this work will lead to novel therapeutic options to treat and prevent scleroderma.

You may return to the list of research that we have funded.
Translate »

Connect with ANRF Today!

Stay up -to-date with the latest arthritis news, stories and info.​

Make a Donation

Make a one-time or recurring donation and know that you are making a difference by funding cutting-edge arthritis research.

Skip to content